A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when treating cancer-associated thrombosis (CAT). These findings may inform decisions on the clinical level as well as policy decisions. The analysis is published in Annals of Internal Medicine.
from Medical Xpress - latest medical and health news stories https://ift.tt/HG63hqy
